Drs Pal and Hammers discuss data and clinical pearls for the use of checkpoint inhibitors in RCC.
This activity is intended for hematologists/oncologists and urologists.
The goal of this activity is to improve knowledge and competence related to the role of immune checkpoint inhibitors (ICIs) as monotherapy and combination therapy for patients with renal cell carcinoma (RCC).
- Have increased knowledge regarding the clinical trial data related to ICIs for the treatment of RCC
- Have greater competence related to selecting patients with RCC who are appropriate candidates to receive ICI therapy
Approximate Time to Complete: 30 minutes
Credit Available: Jan. 21, 2020 - Jan. 21, 2021
Developed through a partnership between SITC and Medscape.